The University of Colorado signs licensing agreement with Syndax Pharmaceuticals to treat lung cancer.
Syndax Pharmaceutical has signed an exclusive licensing agreement with the University of Colorado (CU) to commercialise and market a lung cancer treatment developed at the CU School of Medicine. The treatment targets non-small-cell lung carncinoma (NSCLC), which makes up nearly 80% of lung cancers. NSCLCs are much more resistant to chemotherapy and radiation as opposed…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
